Contents
Diarrhea is a common presentation in renal transplant recipients. Causes range from self-limiting gastrointestinal infections to medication-related side effects and opportunistic infections.
Although clinicians understandably focus on dehydration, electrolyte disturbances and infectious causes, a crucial consequence may be overlooked: diarrhea can significantly increase tacrolimus exposure and cause potentially severe drug toxicity.
Understanding this interaction is particularly important because tacrolimus has a narrow therapeutic index, and changes in its concentration can have serious consequences for allograft function.
Why tacrolimus levels may rise during diarrhea
Tacrolimus is a calcineurin inhibitor commonly used to prevent rejection after kidney transplantation. Its pharmacokinetics are complex, with significant variability between patients. They are influenced by gastrointestinal absorption, hepatic metabolism, drug interactions and genetic factors.
Tacrolimus is metabolized predominantly by cytochrome P450 3A enzymes (particularly CYP3A4 and CYP3A5). It is also a substrate of P-glycoprotein, a transport protein in the intestinal wall that limits drug absorption by carrying tacrolimus back into the intestinal lumen.
During diarrhea, intestinal inflammation and epithelial injury may reduce intestinal CYP3A activity and P-glycoprotein function. As a result, more tacrolimus can reach the systemic circulation, raising blood concentrations even though the dose has not changed.
This can seem counterintuitive. Clinicians may initially assume that rapid gastrointestinal transit reduces drug absorption. In transplant recipients, however, diarrhea can produce the opposite effect.
The increase in tacrolimus exposure may persist even after diarrhea resolves, reflecting the time required for intestinal enzyme and transporter activity to recover.
Recognizing tacrolimus toxicity
Tacrolimus toxicity can present with renal, neurological, metabolic and cardiovascular manifestations.
Acute kidney injury is particularly important in kidney transplant recipients. Tacrolimus can cause renal vasoconstriction, reducing renal blood flow and glomerular filtration. A patient presenting with diarrhea and a rising creatinine may therefore have more than one contributing mechanism at the same time: volume depletion, infection and calcineurin inhibitor toxicity.
Neurological symptoms include tremor, headache and paresthesia. More severe, although less common, toxicity can produce confusion, seizures or posterior reversible encephalopathy syndrome (PRES).
Other recognized effects include hyperkalemia, hypomagnesemia, hypertension and disturbances of glucose metabolism.
These findings are not specific to tacrolimus toxicity. Their presence should trigger a broader clinical assessment rather than an assumption that an elevated tacrolimus concentration fully explains each abnormality.
A structured clinical assessment
When a renal transplant recipient presents with diarrhea, the initial assessment should establish the severity of illness, hydration status, allograft function and potential infectious causes.
The history should cover symptom duration, stool frequency, fever, abdominal pain, vomiting, recent travel, exposure to antimicrobials and other medications, and sick contacts.
Mycophenolate mofetil, commonly part of the immunosuppressive regimen in renal transplant recipients, is a frequent contributor to gastrointestinal symptoms.
Infectious differentials include common bacterial and viral gastroenteritis and cytomegalovirus gastrointestinal disease. Norovirus is particularly relevant because infection may persist in immunosuppressed patients.
Initial investigations generally include renal function, electrolytes including magnesium, a complete blood count and a tacrolimus trough concentration. Microbiological investigations should be guided by symptom severity, duration and the patient's immunological risk.
The tacrolimus result must be interpreted cautiously. For twice-daily immediate-release formulations, the usual trough sample is taken approximately 12 hours after the preceding dose, immediately before the next dose. An incorrectly timed sample can lead to inappropriate dose changes.
Management: more than simply reducing the dose
Management begins with identifying and treating the underlying cause of diarrhea and correcting fluid and electrolyte imbalances.
The transplant team should be involved early when there is acute kidney injury, significant gastrointestinal illness, a marked rise in tacrolimus levels or uncertainty about immunosuppression management.
An elevated tacrolimus concentration may require dose reduction or temporary withholding. These decisions must be balanced against the risk of under-immunosuppression and rejection.
Importantly, there is no universal tacrolimus target that applies to every transplant recipient. Target concentrations depend on factors including time since transplantation, immunological risk, previous rejection and local immunosuppression protocols. Repeat trough concentrations are often required during the illness and after recovery.
A dose that appears safe during active diarrhea may become inappropriate once intestinal function normalizes.
Clinicians should also review interacting medications. Macrolide antibiotics, azole antifungals and certain calcium-channel blockers can increase tacrolimus concentrations by inhibiting CYP3A metabolism.
Changes to other immunosuppressive agents, particularly mycophenolate, should also be considered carefully. Although dose reduction may sometimes be necessary during severe gastrointestinal illness, uncoordinated changes can increase the risk of rejection.
Why follow-up matters
A single satisfactory tacrolimus result does not necessarily exclude subsequent toxicity.
The relationship between diarrhea and tacrolimus exposure is not linear: concentrations may rise as gastrointestinal inflammation evolves and remain elevated even after symptoms improve.
Patients discharged after a diarrheal illness will therefore require early repeat blood tests, particularly if their tacrolimus dose was changed during their admission.
Clear discharge documentation should specify the current tacrolimus formulation and dose, the most recent concentration, the target therapeutic range and the arrangements for repeat monitoring.
Clinical lessons
- Diarrhea in a transplant recipient should trigger consideration of altered tacrolimus exposure, even when the dose has not changed.
- Acute kidney injury may be multifactorial. Dehydration and tacrolimus nephrotoxicity can occur at the same time, and neither excludes infection, obstruction or other allograft pathology.
- Tacrolimus concentrations must be interpreted using the correct sampling interval and the patient's individual target range.
- Monitoring should continue beyond the immediate illness, as tacrolimus exposure can change again after intestinal function recovers.
Conclusion
Diarrhea in kidney transplant recipients is not only a gastrointestinal problem. It can substantially alter tacrolimus pharmacokinetics and create a risk of nephrotoxicity, among other complications.
For clinicians outside specialist transplant services, the most important message is straightforward: when a patient taking tacrolimus develops significant diarrhea, checking the trough concentration and discussing management with the transplant team early are essential.
Sources
- Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant. 2005;5(6):1383-1391. PubMed
- Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623-653. PubMed
- Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003;18(11):2409-2414. PubMed
- Maes BD, Lemahieu W, Kuypers D, et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant. 2002;2(10):989-992. PubMed
- Sato K, Amada N, Sato T, et al. Severe elevations of FK506 blood concentration due to diarrhea in renal transplant recipients. Clin Transplant. 2004;18(5):585-590. PubMed
- van Boekel GAJ, Aarnoutse RE, van der Heijden JJ, et al. Effect of mild diarrhea on tacrolimus exposure. Transplantation. 2012;94(7):763-767. PubMed
- Asano T, Nishimoto K, Hayakawa M. Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proc. 2004;36(7):2096-2097. PubMed
- U.S. Food and Drug Administration. Prograf (tacrolimus) prescribing information. 2023. FDA label (PDF)
More from MedRise: MedRise for residents and fellows and more MedRise Articles.
This contributor article reflects the author's own views and experience. It is for education only and is not medical, legal or career advice.




Comments
Comments are reviewed before they appear. Share your reasoning, your experience or a question for the author. No patient details, no medical advice for individual cases and no links. Comment rules.
Thank you. Your comment was received and will appear after review, usually within a few hours.
Your comment was not sent. Please add your name, a valid email and at least 20 characters, and tick the box.
Links are not allowed in comments. Please remove them and send it again.
You have reached today's comment limit. Please try again tomorrow.